From NYSE: Anthropic called out Manifold Bio as a key feedback provider when they announced Claude for life sciences recently. CEO Gleb Kuznetsov explains, and updates us on the brain shuttle program
He describes why Manifold is focused on in vivo work, even to the extent that it is trying to develop a 'virtual organism'. Plus, an update on the brain shuttle program that is partnered with Roche (it is not a transferrin program), and he explains the Anthropic news.










.png)